Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

NCT07185373 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

215

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: Teniposide
DRUG: Orelabrutinib
DRUG: MTX
DRUG: Rituximab (R)
DRUG: Dexamethasone

Sponsor

Huashan Hospital